Updates in the Diffuse Large B-Cell Lymphoma Treatment Landscape
Ashley Ames, FNP-BC, and Diane Lee, AGPCNP-BC
From Memorial Sloan Kettering Cancer Center, New York, New York
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2022;13(3):341–344 |
© 2022 Harborside™
During JADPRO Live Virtual 2021, presenters discussed updates in the treatment of diffuse large B-cell lymphoma (DLBCL), including novel agents and chimeric antigen receptor (CAR) T-cell therapy, and how the treatment and management of patients with DLBCL has been affected by the COVID-19 pandemic.
For access to the full length article, please sign in